Current use of clozapine in Parkinson disease and related disorders

Clinical Neuropharmacology

Volumn 33, Issue 1, 2010, Pages 14-16

  Thomas, Alissa A ^a   Friedman, Joseph H ^a,b  

^a BROWN UNIVERSITY   (United States)

^b NeuroHealth   (United States)

Author keywords

Agranulocytosis; Clozapine; Parkinson disease; Parkinson psychosis; Sedation; Tremor

Indexed keywords

AMANTADINE; ANTIDIABETIC AGENT; CLONAZEPAM; CLOZAPINE; DONEPEZIL; ENTACAPONE; GALANTAMINE; HYPOCHOLESTEROLEMIC AGENT; LEVODOPA; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE;

ADULT; ADVERSE OUTCOME; AGED; AGITATION; AGRANULOCYTOSIS; ARTICLE; BEHAVIOR DISORDER; CONFUSION; CONSTIPATION; CORTICOBASAL DEGENERATION; DIFFUSE LEWY BODY DISEASE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HALLUCINATION; HOSPICE CARE; HUMAN; HYPERSALIVATION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOCLONUS; NEUTROPHIL COUNT; OUTPATIENT DEPARTMENT; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; UNITED STATES; WEAKNESS; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CLOZAPINE; DRUG UTILIZATION; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSONIAN DISORDERS; RETROSPECTIVE STUDIES; TREMOR;

EID: 76749108953     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181c47168     Document Type: Article

References (17)

1. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15(2): 201-211.
2. Fox SH, Chuang F, Brotchie JM. Parkinson's diseaseVopportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res 2008;172:479-494.
3. Poewe W. When a Parkinson's disease patient starts to hallucinate. Pract Neurol 2008;8:238-241.
4. Ondo WG, Tinter R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963.
5. Rabey JM, Prokhorov T, Minovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months duration. Mov Disord 2007;22:313-318.
6. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999; 340(10):757-763.
7. Pollack P, Tison F, Rascol O, et al. Clozapine in drug induced ps-chosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-695.
8. Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurolog- 1997;4:1077-1081.
9. Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004;19(7):831-833.
10. Miyasaki JM, Shannon K, Voon V, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):996-1002.
11. Friedman JH. Atypical antipsychotics and the Bblack box[ warning. Neurology 2006;67:564-566.
12. Ballard C, Hanne- ML, Theodoulou M, et al DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow up of randomized placebo-controlled trial. Lancet Neurol 2009;8:151-157.
13. Ra- WA, Chung CP, Murray KT, et al Atypical antipsychotic drugs and the risk of sudden cardiac death. N Eng J Med 2009;360: 225-235.
14. Gomide L, Kummer A, Cardoso F, et al. Use of clozapine in Brazilian patients with Parkinson's disease. Arq Neuropsiquiatr 2008;66(3-B):611-614.
15. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7(2):125-131.
16. Factor SA, Friedman JH, Lannon MC, et al. The Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16(1):135-139.
17. Bennett JP Jr, Landow ER, Dietrich S, et al. Suppression of d-skinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction Mov Disord 1994;9: 409-414.